SCHEDULE: Morgan Stanley Discloses IMMUNIC Stake

Morgan Stanley has filed a Schedule 13G, reporting beneficial ownership of 5.2% of IMMUNIC, INC. common stock as of September 30, 2026.

Summary

• Morgan Stanley has filed a Schedule 13G, indicating it beneficially owns 704,244 shares of IMMUNIC, INC. common stock.
• This represents 5.2% of the total class of securities.
• The filing is dated November 13, 2026, and reflects the ownership as of September 30, 2026.
• Morgan Stanley is identified as a broker-dealer, investment adviser, or similar entity.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily a routine disclosure of beneficial ownership by a financial institution, with no significant new operational or financial information.

Positives

• Morgan Stanley's filing confirms a significant institutional investor's stake in IMMUNIC, INC., which can be seen as a sign of confidence in the company's potential.
• The disclosure is routine and indicates normal business operations for Morgan Stanley.

Negatives

• The filing does not provide any new operational or financial performance data for IMMUNIC, INC., offering no insight into the company's current business health.
• The information is purely a disclosure of ownership, not an endorsement or strategic commentary on IMMUNIC, INC.

Risks

• The filing does not contain specific risk factors related to IMMUNIC, INC.'s business operations or future prospects.
• The primary risk is that this is a standard disclosure and does not reflect any new strategic developments or positive outlook for IMMUNIC, INC.

Future Outlook

The filing contains no forward-looking statements or guidance regarding IMMUNIC, INC.'s future performance. It is a disclosure of current beneficial ownership.

Management Comments

• "In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS")."
• "This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. This filing indicates Morgan Stanley's role as a significant holder of IMMUNIC, INC. shares, typical for financial institutions managing client assets or proprietary trading.

Stakeholder Impact

• Shareholders: The filing confirms a substantial institutional investor's presence, which may influence market perception but does not directly alter existing share value or rights.
• Creditors: No direct impact as the filing pertains to equity ownership and not debt.
• Employees: No direct impact indicated by this ownership disclosure.
• Suppliers/Customers: No direct impact indicated by this ownership disclosure.

Next Steps

• Morgan Stanley will continue to hold its beneficial ownership of IMMUNIC, INC. shares in the ordinary course of business.
• IMMUNIC, INC. will continue its operations and disclosures as per regulatory requirements.

Key Dates

Keywords

beneficial ownership, Schedule 13G, institutional investor, Morgan Stanley, IMMUNIC, INC., common stock, securities